Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain

– Treatment with VX-548 led to statistically significant improvement in pain compared to placebo as well as a clinically meaningful reduction in pain from baseline in both the abdominoplasty and...

Related Keywords

Boston ,Massachusetts ,United States ,London ,City Of ,United Kingdom ,Australia ,America ,Jessica Oswald ,Reshma Kewalramani ,Youtube ,Exchange Commission ,Vertex Pharmaceuticals Conference Call ,Facebook ,Linkedin ,Vertex Pharmaceuticals Incorporated Nasdaq ,Companies To Work ,Drug Administration ,Instagram ,Vertex Pharmaceuticals Incorporated ,Acute Pain Following Abdominoplasty ,Business Wire ,Numeric Pain Rating Scale ,Patients Undergoing ,Key Secondary Outcomes ,Acute Pain Following ,From Baseline ,Acute Pain Following Bunionectomy ,Effectiveness Study ,New Drug Application ,Breakthrough Therapy ,Fast Track ,Pharmaceuticals Conference Call ,North America ,Latin America ,Top Employers ,Private Securities Litigation Reform Act ,Markets ,